Literature DB >> 12544777

Acute blindness as a presenting sign in childhood non-Hodgkin lymphoma.

Elif Güler1, Tezer Kutluk, Nejat Akalan, Canan Akyüz, Lale Atahan, Münevver Büyükpamukçu.   

Abstract

Non-Hodgkin lymphoma is the third most common malignancy in childhood. Occasionally, a patient with lymphoma may present with neuroophthalmologic symptoms and signs. It is usually associated with 3rd, 4th, and 6th cranial nerve palsies. Here, we report three children presenting with loss of vision. Two of them were cured with modified LMB-89 (lymphoma malignant B) chemotherapy regimen and radiotherapy. In one patient, loss of vision returned to normal in the left eye but persisted in the right eye. The second patient suffered from permanent visual loss, although the primary disease responded well to treatment. Unfortunately, the third patient died at an early phase of treatment. Acute blindness as a presenting symptom is rare in lymphoma. Early diagnosis and treatment is critical to increase the survival rate and to improve the quality of the vision.

Entities:  

Mesh:

Year:  2003        PMID: 12544777     DOI: 10.1097/00043426-200301000-00014

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Atypical manifestation of childhood primary cerebral lymphoma restricted to the leptomeninges.

Authors:  Birgit Uhlenberg; Susanne Reich; Verena Varnholt; Frank K H van Landeghem; Ianina Scheer; Dietrich Berdel; Arend von Stackelberg; Arpad von Moers
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

2.  Giant prolactinomas in adolescence: an uncommon cause of blindness.

Authors:  Patrick Semple; Graham Fieggen; Jeannette Parkes; Naomi Levitt
Journal:  Childs Nerv Syst       Date:  2006-09-16       Impact factor: 1.475

3.  Pachymeningeal Involvement with Blindness as the Presenting Manifestation of Non-Hodgkin Lymphoma.

Authors:  Charanpreet Singh; Arjun Lakshman; Aditya Jandial; Sudha Sharma; Ram Nampoothiri; Gaurav Prakash; Pankaj Malhotra
Journal:  Turk J Haematol       Date:  2016-11-22       Impact factor: 1.831

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.